Development of a realistic in vivo bone metastasis model of human renal cell carcinoma

Clinical and Experimental Metastasis

Volumn 31, Issue 5, 2014, Pages 573-584

  Valta, Maija P ^a,b   Zhao, Hongjuan ^a   Ingels, Alexandre ^a,c   Thong, Alan E ^a   Nolley, Rosalie ^a   Saar, Matthias ^a,d   Peehl, Donna M ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

^c BICÊTRE HOSPITAL   (France)

^d SAARLAND UNIVERSITY   (Germany)

Author keywords

Bone metastasis; Renal cell carcinoma; Therapy response; Tumorgrafts

Indexed keywords

TEMSIROLIMUS;

ADULT; AGED; ANIMAL TISSUE; ARTICLE; BONE METASTASIS; DISEASE COURSE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; KIDNEY CARCINOMA; MALE; MIDDLE AGED; MOUSE; NONHUMAN; TISSUE SLICE; TREATMENT RESPONSE; TUMOR CELL INOCULATION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; BONE NEOPLASMS; CARCINOMA, RENAL CELL; CELL SURVIVAL; DISEASE MODELS, ANIMAL; FEMALE; HETEROGRAFTS; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MALE; MICE; MICE, KNOCKOUT; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; OSTEOLYSIS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84902295901     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-014-9651-8     Document Type: Article

References (49)

1. Bianchi M, Sun M, Jeldres C, Shariat SF, Trinh QD, Briganti A, Tian Z, Schmitges J, Graefen M, Perrotte P, Menon M, Montorsi F, Karakiewicz PI (2012) Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann Oncol 23(4):973-980
2. Woodward E, Jagdev S, McParland L, Clark K, Gregory W, Newsham A, Rogerson S, Hayward K, Selby P, Brown J (2011) Skeletal complications and survival in renal cancer patients with bone metastases. Bone 48(1):160-166
3. McKay RR, Kroeger N, Xie W, Lee JL, Knox JJ, Bjarnason GA, Mackenzie MJ, Wood L, Srinivas S, Vaishampayan UN, Rha SY, Pal SK, Donskov F, Tantravahi SK, Rini BI, Heng DY, Choueiri TK (2013) Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. Eur Urol 65(3):577-584
4. Molina AM, Jia X, Feldman DR, Hsieh JJ, Ginsberg MS, Velasco S, Patil S, Motzer RJ (2013) Long-term response to sunitinib therapy for metastatic renal cell carcinoma. Clin Genitourin Cancer 11(3):297-302
5. Shinohara N, Nonomura K, Abe T, Maruyama S, Kamai T, Takahashi M, Tatsugami K, Yokoi S, Deguchi T, Kanayama H, Oba K, Naito S (2012) A new prognostic classification for overall survival in Asian patients with previously untreated metastatic renal cell carcinoma. Cancer Sci 103(9):1695-1700
6. Naito S, Yamamoto N, Takayama T, Muramoto M, Shinohara N, Nishiyama K, Takahashi A, Maruyama R, Saika T, Hoshi S, Nagao K, Yamamoto S, Sugimura I, Uemura H, Koga S, Takahashi M, Ito F, Ozono S, Terachi T, Tomita Y (2010) Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients. Eur Urol 57(2):317-325
7. Keizman D, Ish-Shalom M, Pili R, Hammers H, Eisenberger MA, Sinibaldi V, Boursi B, Maimon N, Gottfried M, Hayat H, Peer A, Kovel S, Sella A, Berger R, Carducci MA (2012) Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma. Eur J Cancer 48(7):1031-1037
8. Lipton A, Colombo-Berra A, Bukowski RM, Rosen L, Zheng M, Urbanowitz G (2004) Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid. Clin Cancer Res 10(18 Pt 2):6397S-6403S
9. Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H (2011) Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29(9):1125-1132
10. Beuselinck B, Wolter P, Karadimou A, Elaidi R, Dumez H, Rogiers A, Van Cann T, Willems L, Body JJ, Berkers J, Van Poppel H, Lerut E, Debruyne P, Paridaens R, Schoffski P (2012) Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases. Br J Cancer 107(10):1665-1671
11. Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Lewis, Chen HS, Feuer EJ, KA C (2012) SEER Cancer Statistics Review, 1975-2010. National Cancer Institute, Bethesda
12. Strube A, Stepina E, Mumberg D, Scholz A, Hauff P, Kakonen SM (2010) Characterization of a new renal cell carcinoma bone metastasis mouse model. Clin Exp Metastasis 27(5):319-330
13. Josson S, Nomura T, Lin JT, Huang WC, Wu D, Zhau HE, Zayzafoon M, Weizmann MN, Gururajan M, Chung LW (2011) β2-microglobulin induces epithelial to mesenchymal transition and confers cancer lethality and bone metastasis in human cancer cells. Cancer Res 71(7):2600-2610
14. Kobayashi M, Morita T, Chun NA, Matsui A, Takahashi M, Murakami T (2012) Effect of host immunity on metastatic potential in renal cell carcinoma: the assessment of optimal in vivo models to study metastatic behavior of renal cancer cells. Tumour Biol 33(2):551-559
15. Weber K, Doucet M, Kominsky S (2007) Renal cell carcinoma bone metastasis - elucidating the molecular targets. Cancer Metastasis Rev 26(3-4):691-704
16. Weber KL, Pathak S, Multani AS, Price JE (2002) Characterization of a renal cell carcinoma cell line derived from a human bone metastasis and establishment of an experimental nude mouse model. J Urol 168(2):774-779
17. Wang J, Chen A, Yang C, Zeng H, Qi J, Guo FJ (2012) A bone-seeking clone exhibits different biological properties from the ACHN parental human renal cell carcinoma in vivo and in vitro. Oncol Rep 27(4):1104-1110
18. Maita S, Yuasa T, Tsuchiya N, Mitobe Y, Narita S, Horikawa Y, Hatake K, Fukui I, Kimura S, Maekawa T, Habuchi T (2012) Antitumor effect of sunitinib against skeletal metastatic renal cell carcinoma through inhibition of osteoclast function. Int J Cancer 130(3):677-684
19. Peterson JK, Houghton PJ (2004) Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development. Eur J Cancer 40(6):837-844
20. Sausville EA, Burger AM (2006) Contributions of human tumor xenografts to anticancer drug development. Cancer Res 66(7):3351-3354
21. Ocana A, Pandiella A, Siu LL, Tannock IF (2011) Preclinical development of molecular-targeted agents for cancer. Nat Rev Clin Oncol 8(4):200-209
22. Dennis C (2012) Mouse 'avatars' could aid pancreatic cancer therapy. Nat News. doi: 10.1038/nature.2012.10259
23. DeRose YS, Wang G, Lin YC, Bernard PS, Buys SS, Ebbert MT, Factor R, Matsen C, Milash BA, Nelson E, Neumayer L, Randall RL, Stijleman IJ, Welm BE, Welm AL (2011) Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med 17(11):1514-1520
24. Garber K (2007) Personal mouse colonies give hope for pancreatic cancer patients. J Natl Cancer Inst 99(2):105-107
25. Garber K (2009) From human to mouse and back: 'tumorgraft' models surge in popularity. J Natl Cancer Inst 101(1):6-8
26. Hidalgo M, Bruckheimer E, Rajeshkumar NV, Garrido-Laguna I, De Oliveira E, Rubio-Viqueira B, Strawn S, Wick MJ, Martell J, Sidransky D (2011) A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Ther 10(8):1311-1316
27. Thong AE, Zhao H, Ingels A, Valta MP, Nolley R, Santos J, Young SR, Peehl DM (2013) Tissue slice grafts of human renal cell carcinoma: An authentic preclinical model with high engraftment rate and metastatic potential. Urol Oncol 32(1):43.e23-43.e30
28. Huang D, Ding Y, Li Y, Luo WM, Zhang ZF, Snider J, Vandenbeldt K, Qian CN, Teh BT (2010) Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma. Cancer Res 70(3):1053-1062
29. Zhao H, Nolley R, Chen Z, Peehl DM (2010) Tissue slice grafts: an in vivo model of human prostate androgen signaling. Am J Pathol 177(1):229-239
30. Fisher RL, Vickers AE (2013) Preparation and culture of precision-cut organ slices from human and animal. Xenobiotica; the fate of foreign compounds in biological systems 43(1):8-14
31. Ingels A, Zhao H, Thong A, Saar M, Valta M, Nolley R, Santos J, Peehl DM (2013) Pre-clinical trial of a new dual mTOR inhibitor INK128 for renal cell carcinoma. Int J Cancer 134(10):2322-2329
32. Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, Mundy GR, Boyce BF (1995) Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 10(10):1478-1487
33. Valta MP, Tuomela J, Bjartell A, Valve E, Vaananen HK, Harkonen P (2008) FGF-8 is involved in bone metastasis of prostate cancer. Int J Cancer 123(1):22-31
34. Zhao H, Nolley R, Chen Z, Reese SW, Peehl DM (2008) Inhibition of monoamine oxidase A promotes secretory differentiation in basal prostatic epithelial cells. Differentiation 76(7):820-830
35. Wang J, Chou CH, Blankson J, Satoh M, Knuth MW, Eisenberg RA, Pisetsky DS, Reeves WH (1993) Murine monoclonal antibodies specific for conserved and non-conserved antigenic determinants of the human and murine Ku autoantigens. Mol Biol Rep 18(1):15-28
36. Saylor PJ, Armstrong AJ, Fizazi K, Freedland S, Saad F, Smith MR, Tombal B, Pienta K (2013) New and emerging therapies for bone metastases in genitourinary cancers. Eur Urol 63(2):309-320
37. Grisanzio C, Seeley A, Chang M, Collins M, Di Napoli A, Cheng SC, Percy A, Beroukhim R, Signoretti S (2011) Orthotopic xenografts of RCC retain histological, immunophenotypic and genetic features of tumours in patients. J Pathol 225(2):212-221
38. van Rijn RS, Simonetti ER, Hagenbeek A, Hogenes MC, de Weger RA, Canninga-van Dijk MR, Weijer K, Spits H, Storm G, van Bloois L, Rijkers G, Martens AC, Ebeling SB (2003) A new xenograft model for graft-versus-host disease by intravenous transfer of human peripheral blood mononuclear cells in RAG2-/- gammac-/- double-mutant mice. Blood 102(7):2522-2531
39. Rozemuller H, Knaan-Shanzer S, Hagenbeek A, van Bloois L, Storm G, Martens AC (2004) Enhanced engraftment of human cells in RAG2/gammac double-knockout mice after treatment with CL2MDP liposomes. Exp Hematol 32(11):1118-1125
40. An Z, Jiang P, Wang X, Moossa AR, Hoffman RM (1999) Development of a high metastatic orthotopic model of human renal cell carcinoma in nude mice: benefits of fragment implantation compared to cell-suspension injection. Clin Exp Metastasis 17(3):265-270
41. Zhang XH, Jin X, Malladi S, Zou Y, Wen YH, Brogi E, Smid M, Foekens JA, Massague J (2013) Selection of bone metastasis seeds by mesenchymal signals in the primary tumor stroma. Cell 154(5):1060-1073
42. Hoffmann NE, Gillett MD, Cheville JC, Lohse CM, Leibovich BC, Blute ML (2008) Differences in organ system of distant metastasis by renal cell carcinoma subtype. J Urol 179(2):474-477
43. Sahi C, Knox JJ, Clemons M, Joshua AM, Broom R (2010) Renal cell carcinoma bone metastases: clinical advances. Ther Adv Med Oncol 2(2):75-83
44. Vrdoljak E, Rini B, Schmidinger M, Omrcen T, Torday L, Szczylik C, Sella A (2013) Bisphosphonates and vascular endothelial growth factor-targeted drugs in the treatment of patients with renal cell carcinoma metastatic to bone. Anticancer Drugs 24(5):431-440
45. Wood SL, Brown JE (2012) Skeletal metastasis in renal cell carcinoma: current and future management options. Cancer Treat Rev 38(4):284-291
46. Vaishampayan U (2013) Cabozantinib as a novel therapy for renal cell carcinoma. Curr Oncol Rep 15(2):76-82
47. Pal SK, Quinn DI (2013) Differentiating mTOR inhibitors in renal cell carcinoma. Cancer Treat Rev 39(7):709-719
48. Okui T, Shimo T, Fukazawa T, Kurio N, Hassan NM, Honami T, Takaoka M, Naomoto Y, Sasaki A (2010) Antitumor effect of temsirolimus against oral squamous cell carcinoma associated with bone destruction. Mol Cancer Ther 9(11):2960-2969
49. Hussein O, Tiedemann K, Murshed M, Komarova SV (2012) Rapamycin inhibits osteolysis and improves survival in a model of experimental bone metastases. Cancer Lett 314(2):176-184